Skip Navigation
  Print Page

Diabetes: Research Activities and Scientific Advances

Skip sharing on social media links
Share this:

Institute Activities and Advances

The NICHD research portfolio includes sizable efforts on diabetes within the context of preventing chronic disease and of understanding the early origins of health and disease. Projects on diabetes, its risk factors, and its associated conditions and outcomes are spread across multiple organizational units and include several large international clinical studies. Some of this research is described below.

The Pediatric Growth and Nutrition Branch (PGNB) supports research on multiple aspects of type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). Research priorities include developing methods for detecting potential diabetics in childhood and for developing successful techniques of immunomodulation to prevent or mitigate the body's immune attack on the pancreatic beta cell. Branch research has also pioneered immunogenetic methods that stratify levels of risk for T1DM. In addition to projects led by individual investigators, the PGNB also supports several large, long-term clinical studies and networks in the United States and abroad. Visit the Other Activities and Advances section for details on these projects.

Recent research findings from PGNB-supported researchers include the following:

Researchers Test a New Approach to Reduce Immune Reactions in T1DM

The most common form of T1DM is caused by an autoimmune reaction (the body attacks its own healthy cells) that destroys the insulin-producing beta (β) cells of the pancreas. Because most newly diagnosed patients with diabetes still produce significant amounts of insulin, preserving remaining β-cell function is desirable to reduce short- and long-term complications of the disease. Because T cells of the immune system play a central role in the T1DM autoimmune reaction, researchers investigated whether a drug that works to partially block T-cell function could benefit patients with early-stage T1DM.

In a randomized clinical trial involving 112 patients, 77 were assigned to receive treatment with abatacept, a drug used to treat rheumatoid arthritis (also an autoimmune disease) by blocking the activity of T cells. The remaining patients received placebo treatments. The results showed that abatacept had an early beneficial effect in slowing the reduction in β-cell function. However, over a 24-month period, the drop in β-cell function in the abatacept group paralleled that in the placebo group. Moreover, patients receiving abatacept had similar insulin doses at the end of the study, although the abatacept patients did produce slightly more insulin from their own bodies. Although these results indicated that abatacept is not appropriate for clinical use at this time, scientists are planning further studies to see if abatacept might be useful as part of a combination therapy in early-stage T1DM.  (PMID: 21719096)

Pilot study shows hydrolysed formula may promote beta cell autoimmunity and reduce diabetes risk

The NICHD is supporting a randomized controlled trial, at 77 sites in 15 countries, of a nutritional intervention to reduce T1DM in children who are at increased genetic risk for this autoimmune disease. The trial is designed to determine whether weaning infants from the breast to a cow’s milk-based formula in which the milk proteins have been hydrolysed reduces their risk for T1DM. 

Results from a small pilot study of 230 genetically at-risk infants were highly encouraging. This research showed a 50% reduction in appearance of autoantibodies directed against the insulin producing cells (β cells) of the pancreas in the group assigned to protein hydrolysate formula. These autoantibodies are used as markers of diabetes risk and appear to be involved in the attack on the β cells. (PMID: 21064382)

Stem Cell Treatment Controls Diabetes in Mice

Stem cells offer a promising approach for producing the cell types needed to replace damaged cells in diabetes-related disorders. Diabetes is a disease long thought to be amenable to stem-cell therapy because T1DM, at least, is caused by the loss of the single type of cell that produces insulin and, therefore, might be cured by providing patients with insulin-producing cells produced in the laboratory.

The uterus contains numerous stem cells needed to make the new cells that replenish the uterine lining every month. Researchers took this rich source of stem cells and added various nutrients and growth factors that caused the cells to “differentiate” into insulin-producing cells. These cells were injected into a diabetic mouse model where they secreted insulin and stabilized blood glucose levels. In contrast, mice injected with control cells had high blood glucose levels, weight loss, and eye problems—conditions that develop in human diabetics if their blood glucose is not properly controlled. This impressive example of stem cell-based therapy suggests that individuals could successfully be treated for diabetes or other disorders using cells from the lining of the uterus. Such research is an excellent example of the potential of stem-cell therapy to effectively address major chronic disorders. (PMID: 21878900)

Glutamic Acid Decarboxylase (GAD) Not An Effective Therapy for Patients with Early-Stage T1DM

As noted above, the most common form of T1DM is caused by an autoimmune reaction that destroys the insulin-producing β cells of the pancreas. Scientists are investigating whether the progression of T1DM can be slowed by preserving the body’s own secretion of insulin, especially if effective interventions can be provided in the early stages of the disease. In previous studies conducted in mice, GAD showed promise as a possible treatment for T1DM. Scientists attempted to translate this success in animal studies to treatment of T1DM in humans. In a randomized clinical trial, researchers gave two or three doses of three different formulations of GAD injections to 145 patients in the early stages of type 1 diabetes. They assessed the patients’ progress after 1 year. Unfortunately, the GAD-based treatment was not shown to slow the loss of insulin secretion in diabetes patients. (PMID: 21714999)

Doctor-Patient Communication Affects Medication Adherence

Besides the PGNB, other NICHD extramural and intramural research units support and conduct research on diabetes. One of these is the extramural Population Dynamics Branch (PDB), which supports research and research training in demography, reproductive health, and population health.

Researchers supported by the PDB published research describing how doctor-patient communication can affects medication adherence. Because diabetes increases the risk of serious illnesses, many people with diabetes are prescribed medication to manage their blood sugar, lower cholesterol, and/or reduce blood pressure. These treatments are important for living a long and healthy life, but many people with diabetes do not take their medications as prescribed. Researchers assessed how the doctor-patient relationship affects whether patients take their medicine (medication adherence). The scientists reviewed medical records and surveyed over 9,000 people with diabetes who were covered by the same insurance plan and were prescribed medication to manage blood sugar, lower cholesterol, and/or reduce blood pressure. Unlike previous studies, which simply asked people to report whether they took their medicine, this study used information from medical records about whether patients obtained prescription refills on time. The researchers found that for each different type of medicine (blood pressure, cholesterol, and blood sugar), between 20% and 30% of patients did not obtain as much medication as they were prescribed. Compared with similar patients offering higher ratings, patients who gave lower overall ratings for their communication with their primary care doctor were less likely to obtain their medicine as prescribed. More specifically, for cholesterol and blood sugar medications, patients who rated their doctors poorly for involving patients in decisions, understanding patients’ problems with treatment, and eliciting confidence and trust were less likely to follow their medication regimens. These results indicate that efforts to improve doctor-patient communication and trust may have a significant benefit in improving medication adherence for people with diabetes. (PMID: 23277199)

The Institute’s Pregnancy and Perinatology Branch (PPB) seeks to promote healthy pregnancy, labor, delivery, and infancy by supporting research on multiple topics within each of these critical development periods. PPB research addresses high-risk pregnancies that result from a variety of conditions, including gestational diabetes, as well as studies of safe delivery and neonatal health outcomes. Like the PGNB, the PPB also supports large-scale research studies and networks in addition to projects led by individual investigators.

Researchers in the Division of Intramural Population Health Research are leading multiple studies of diabetes management in adolescents. One of these studies is exploring the effectiveness of a family-focused management plan on diabetes outcomes. Another examines the effect of a program to promote healthful eating. Visit the Division’s Health Behavior Branch to learn more about these studies. In addition, the Division’s Epidemiology Branch is examining the Epidemiology, Etiology, and Health Consequences of Gestational Diabetes to address critical data gaps and to improve detection and management of the condition.

Healthy Diet May Fend Off T2DM After Gestational Diabetes

At least 5% of pregnant women nationwide develop high blood sugar levels, even though they didn’t have diabetes before their pregnancy. This condition, called gestational diabetes, significantly raises a woman’s risk for T2DM later in life. Complications of T2DM include heart disease, stroke, kidney disease, blindness, and amputation. Researchers at DIPHR and their collaborators studied over 4,400 women who developed gestational diabetes to see if a healthy diet could reduce these women’s risk of developing T2DM in the years following their pregnancy. The results showed that women who adhered most closely to healthy diets lowered their risk for T2DM considerably, when compared to women who did not eat healthy. Women with healthy eating habits had between 40% and 57% lower risk of developing T2DM. The results showed that women with gestational diabetes are not always destined to suffer from T2DM in later years, and that a healthy diet is especially important for this high-risk group. (PMID: 22987062)

Other Activities and Advances

The PGNB supports multiple ongoing research trials and networks that focus on understanding diabetes. Some of these projects include:

  • DirecNet External Web Site Policy, the world’s first research network devoted to studying children with T1DM
  • The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, examining the health effects of gestational diabetes in women and their offspring (Find Hyperglycemia and Adverse Pregnancy Outcomes Study PubMed Articles). With the NIDDK, the PGNB launched the HAPO Follow-up Study (HAPO-FUS) in 2013, which will measure the height, weight, blood pressure, body fat, blood sugar, insulin, and blood fats of 7,000 of the original HAPO mothers and their children, who are now 8 to 12 years old, to determine whether there is a long-term effect of the hyperglycemia during pregnancy.
  • Trial to Reduce the Incidence of TIDM in the Genetically at Risk (TRIGR), the first large trials designed to ascertain if a simple nutritional intervention during infancy can delay or prevent the onset of Type 1 diabetes in children at high genetic risk of this condition. Results from a small pilot study of 230 genetically at-risk infants were highly encouraging. This research showed a 50% reduction in appearance of autoantibodies directed against the β cells of the pancreas in the group assigned to protein hydrolysate formula. These autoantibodies are used as markers of diabetes risk and appear to be involved in the attack on the β cells. (PMID: 21067382)  
  • TrialNet External Web Site Policy, a network of 14 diabetes centers dedicated to utilizing a four-prong paradigm to test the ability of biological agents to prevent type 1 diabetes in at-risk children, or to slow the course of the disease in newly diagnosed children

The PPB supports efforts to understand gestational diabetes, its symptoms, and its outcomes through the Maternal-Fetal Medicine Units (MFMU) Network. The MFMU Network studies various types of high-risk pregnancies and pregnancy outcomes, including gestational diabetes, preterm labor and birth, and preeclampsia.

The NICHD is also a sponsor of the Consensus Development Conference on Diagnosing GDM, which aims to better understand the benefits and risks of various GDM screening and diagnostic approaches by assessing the available scientific evidence. In 2013, the panel concluded that there is insufficient evidence that adopting a new diagnostic approach for GDM would provide more benefit than harm. Read the Final Statement of the Consensus Development Conference on Diagnosing GDM.

​​
Last Updated Date: 10/23/2013
Last Reviewed Date: 09/17/2013
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology